Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+breast cancer

被引：0
|
作者：
Buendia-Buendia, Jorge E. [1 ]
Pernas, Sonia [2 ]
Cohen, Ofir [1 ]
Mao, Ping Ping [2 ]
Kowalski, Kailey [2 ]
Lin, Nancy [2 ]
Winer, Eric [2 ]
Wagle, Nikhil [2 ]
机构：
[1] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-01-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-01-09
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HER2+breast cancer: Unresolved challenges
    Winer, E. P.
    CANCER RESEARCH, 2013, 73
  • [22] Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
    Song, Patrick N.
    Mansur, Ameer
    Lu, Yun
    Della Manna, Deborah
    Burns, Andrew
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Yang, Eddy S.
    Sorace, Anna G.
    CANCERS, 2022, 14 (04)
  • [23] Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models
    Sprouffske, Kathleen
    Kerr, Grainne
    Li, Cheng
    Prahallad, Anirudh
    Rebmann, Ramona
    Waehle, Verena
    Naumann, Ulrike
    Bitter, Hans
    Jensen, Michael R.
    Hofmann, Francesco
    Brachmann, Saskia M.
    Ferretti, Stephane
    Kauffmann, Audrey
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 : 323 - 331
  • [24] Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+breast cancer
    Miller, K. D.
    Steding, C. E.
    Prasad, N.
    Rojas, L. A.
    Herbert, B-S
    CANCER RESEARCH, 2012, 72
  • [25] Delineating the mechanisms of resistance to panHER inhibitors in HER2+breast cancer cells
    Kutuk, O.
    Basaga, H.
    Ozmay, Y.
    Karakas, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] The Effect of HER2 Amplification in HER2+Breast Cancer
    Lee, M. K.
    Hurvitz, S. A.
    Tran, B. N.
    Fu, Y.
    Chung, D. U.
    Gornbein, J.
    Apple, S. K.
    Chang, H. R.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S45 - S45
  • [27] Application and challenge of HER2DX genomic assay in HER2+breast cancer treatment
    Ma, Shujuan
    Zhou, Yan
    Ma, Dandan
    Qi, Xiaowei
    Jiang, Jun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4218 - 4235
  • [28] Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+breast cancer
    Branco, Francisco P.
    Machado, Duarte
    Silva, Filipa F.
    Andre, Saudade
    Catarino, Ana
    Madureira, Rosa
    Pinto, Joao M.
    Godinho, Joao P.
    Simoes, Pedro D.
    Brito, Margarida
    Casa-Nova, Mafalda
    Moreira, Antbnio R.
    Passos-Coelho, Jose L.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (09): : 6110 - 6116
  • [29] Patient perspectives on HER2+breast cancer recurrence: Results from an online patient survey
    Jenkins, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] Loss of the tumor and metastasis suppressor RasGAP DAB2IP mediates therapeutic resistance in HER2+breast cancer
    Perurena, Naiara
    Schade, Amy
    Pilla, Natalie
    Loi, Patrick
    Rodriguez, Carrie
    Gardner, Alycia
    Cichowski, Karen
    CANCER RESEARCH, 2024, 84 (03)
12345